BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22541065)

  • 21. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study.
    Kubota K; Murakami K; Inoue T; Itoh H; Saga T; Shiomi S; Hatazawa J
    Ann Nucl Med; 2011 Dec; 25(10):777-86. PubMed ID: 21901365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
    Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
    Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
    Cerfolio RJ; Ojha B; Bryant AS; Raghuveer V; Mountz JM; Bartolucci AA
    Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions.
    Liao CY; Chen JH; Liang JA; Yeh JJ; Kao CH
    Eur J Radiol; 2012 Nov; 81(11):3518-23. PubMed ID: 22436434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.
    Gould MK; Kuschner WG; Rydzak CE; Maclean CC; Demas AN; Shigemitsu H; Chan JK; Owens DK
    Ann Intern Med; 2003 Dec; 139(11):879-92. PubMed ID: 14644890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients.
    Li J; Xu W; Kong F; Sun X; Zuo X
    Surg Oncol; 2013 Sep; 22(3):151-5. PubMed ID: 23664848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis.
    Li B; Li Q; Nie W; Liu S
    Eur J Radiol; 2014 Feb; 83(2):338-44. PubMed ID: 24355655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT.
    Satoh Y; Ichikawa T; Motosugi U; Kimura K; Sou H; Sano K; Araki T
    AJR Am J Roentgenol; 2011 Feb; 196(2):447-53. PubMed ID: 21257899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
    Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
    Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
    Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
    J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
    Manenti G; Cicciò C; Squillaci E; Strigari L; Calabria F; Danieli R; Schillaci O; Simonetti G
    Eur J Radiol; 2012 Aug; 81(8):1917-25. PubMed ID: 21908120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.